目的:我们使用锥形束计算机断层扫描(CBCT)扫描和组织学检查评估了低剂量重组人骨形态发生蛋白2(rhBMP-2)在β-磷酸三钙(β-TCP)上掺入仿生磷酸钙(rhBMP-2/BioCaP/β-TCP)对骨形成的有效性。
方法:将40例接受微创单根拔牙种植牙的患者根据用于牙槽保存的材料随机分为三组:rhBMP-2/BioCaP/β-TCP填充,β-TCP,或自然愈合(保持未填充)(控制)。肺泡窝(包括对照组)用两层胶原膜覆盖并缝合。进行了两次CBCT扫描,一个在插座保存程序(基线)后立即进行,另一个在6周后进行。记录从CBCT获得的灰度值(GVs)。在插入牙种植体的过程中,活检和组织学分析新骨形成,残余材料,和活检核心的未矿化骨组织。
结果:填充材料中心区域CBCT扫描的GV的平均值(±标准偏差)变化如下:rhBMP-2/BioCaP/β-TCP组中的373.19±157.16,β-TCP组112.26±197.25,对照组为-257±273.51。rhBMP-2/BioCaP/β-TCP组的GV与β-TCP组相比有统计学意义(P<0.001)。还发现了新骨形成的差异(P=0.006):rhBMP-2/BioCaP/β-TCP组的21,18%±7.62%,β-TCP组13.44%±6.03%,对照组为9.49%±0.08%。rhBMP-2/BioCaP/β-TCP组的残留量为10.04%±4.57%。β-TCP组20.60%±9.54%)(P<0.001)。还发现未矿化骨组织的差异(P<0.001)(68.78%±7.67%,65.96%±12.64%,rhBMP-2/BioCaP/β-TC中的90.38%±7.5%,β-TCP,和对照组,分别)。
结论:这项研究表明,rhBMP-2/BioCaP/β-TCP是一种有前途的骨替代物,具有快速降解和有效的成骨能力,可用于种植牙科中的牙槽保存。
背景:ChiCTR,ChiCTR2000035263。2020年8月5日注册,https://www。chictr.org.cn/ChiCTR2000035263。
We assessed the efficiency of low-dose recombinant human bone morphogenetic protein-2 (rhBMP-2) incorporated biomimetic calcium phosphate on β-tricalcium phosphate (β-TCP) (rhBMP-2/BioCaP/β-TCP) on bone formation in a model of socket preservation using cone beam computed tomography (CBCT) scanning and histological examination.
Forty patients undergoing minimally invasive single-root tooth extraction for dental implantation were randomized to three groups according to the material used for socket preservation: filling with rhBMP-2/BioCaP/β-TCP, β-TCP, or natural healing (kept unfilled) (controls). The alveolar sockets (including the control group) were covered by two-layer collagen membranes and sutured. Two CBCT scans were taken, one immediately after socket preservation procedure (baseline) and another 6 weeks later. Gray values (GVs) obtained from CBCT were recorded. During insertion of the dental implant, biopsies were taken and analyzed histologically for new bone formation, residual material, and unmineralized bone tissue at the core of the biopsy.
The mean (± standard deviation) changes of GVs of the CBCT scans at the central area of filled materials were as follows: 373.19 ± 157.16 in the rhBMP-2/BioCaP/β-TCP group, 112.26 ± 197.25 in the β-TCP group, and -257 ± 273.51 in the control group. The decrease of GVs in the rhBMP-2/BioCaP/β-TCP group as compared with the β-TCP group was statistically significant (P < 0.001). Differences in new bone formation (P = 0.006) were also found: 21,18% ± 7.62% in the rhBMP-2/BioCaP/β-TCP group, 13.44% ± 6.03% in the β-TCP group, and 9.49% ± 0.08% in controls. The residual material was10.04% ± 4.57% in the rhBMP-2/BioCaP/β-TCP group vs. 20.60% ± 9.54%) in the β-TCP group (P < 0.001). Differences in unmineralized bone tissue (P < 0.001) were also found (68.78% ± 7.67%, 65.96% ± 12.64%, and 90.38% ± 7.5% in the rhBMP-2/BioCaP/β-TC, β-TCP, and control groups, respectively).
This study shows that rhBMP-2/BioCaP/β-TCP is a promising bone substitute with fast degradation and potent pro-osteogenic capacity that can be useful for socket preservation in implant dentistry.
ChiCTR, ChiCTR2000035263. Registered 5 August 2020, https://www.chictr.org.cn/ChiCTR2000035263 .